Inhibiting thrombin activity could treat PVR

Article

Inhibiting thrombin activity may be a treatment option for proliferative vitreoretinopathy (PVR), given that such activity is increased in the vitreous of patients with the disease and is associated with the activation of pro-inflammatory and pro-fibrotic pathways in retinal pigment epithelium (RPE) cells.

Inhibiting thrombin activity may be a treatment option for proliferative vitreoretinopathy (PVR), given that such activity is increased in the vitreous of patients with the disease and is associated with the activation of pro-inflammatory and pro-fibrotic pathways in retinal pigment epithelium (RPE) cells. So say authors of a study published in Investigative Ophthalmology & Visual Science.

The authors, from The Netherlands, collected vitreous samples from 11 patients undergoing vitrectomy for macular holes and puckers, who served as controls; 15 patients with retinal detachment in whom PVR did not develop within 6 months after vitrectomy; 11 patients with retinal detachment in whom PVR did develop within 6 months after vitrectomy; and 14 patients with established PVR. They used a thrombin-specific chromogenic substrate to determine thrombin activity in the vitreous.

The researchers stimulated ARPE-19 cells with diluted vitreous samples with and without hirudin. They used a multiplex approach to analyse samples at 0 and 24 hours to see whether 27 cytokines/chemokines and growth factors were present.

Results showed that thrombin activity was significantly greater in the vitreous of the PVR group compared with the vitreous in the other groups. "PVR vitreous stimulated the production CCL2, CXCL8, GM-CSF, IL-6 and PDGF-BB by ARPE-19 to significantly (P

To read the abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.